Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Cash & Equivalents: 2010-2019

Historic Cash & Equivalents for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $43.4 million.

  • EyePoint Pharmaceuticals' Cash & Equivalents rose 165.38% to $43.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $43.4 million, marking a year-over-year increase of 165.38%. This contributed to the annual value of $38.8 million for FY2018, which is 129.47% up from last year.
  • According to the latest figures from Q1 2019, EyePoint Pharmaceuticals' Cash & Equivalents is $43.4 million, which was down 4.16% from $45.3 million recorded in Q4 2018.
  • EyePoint Pharmaceuticals' 5-year Cash & Equivalents high stood at $55.8 million for Q3 2018, and its period low was $11.2 million during Q4 2015.
  • Moreover, its 3-year median value for Cash & Equivalents was $16.9 million (2017), whereas its average is $28.2 million.
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' Cash & Equivalents tumbled by 62.32% in 2015, and later surged by 371.26% in 2018.
  • EyePoint Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $11.2 million in 2015, then rose by 4.24% to $11.7 million in 2016, then climbed by 10.19% to $12.9 million in 2017, then soared by 251.51% to $45.3 million in 2018, then surged by 165.38% to $43.4 million in 2019.
  • Its last three reported values are $43.4 million in Q1 2019, $45.3 million for Q4 2018, and $55.8 million during Q3 2018.